![]() CP-346086 dihydrate structure
|
Common Name | CP-346086 dihydrate | ||
---|---|---|---|---|
CAS Number | 1262769-98-1 | Molecular Weight | 513.51 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C26H26F3N5O3 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of CP-346086 dihydrateCP-346086 dihydrate is a potent and orally active microsomal triglyceride transfer protein (MTP) inhibitor, with an IC50 of 2.0 nM for human and rodent MTP. CP-346086 dihydrate can lower plasma cholesterol and triglycerides in vivo[1]. |
Name | CP-346086 dihydrate |
---|
Description | CP-346086 dihydrate is a potent and orally active microsomal triglyceride transfer protein (MTP) inhibitor, with an IC50 of 2.0 nM for human and rodent MTP. CP-346086 dihydrate can lower plasma cholesterol and triglycerides in vivo[1]. |
---|---|
Related Catalog | |
Target |
IC50: 2.0 nM (MTP)[1] |
In Vitro | CP-346086 (0.1-1000 nM) dose-dependently inhibits human MTP-mediated triglyceride transfer between vesicles with an IC50 of 2.0 nM[1]. CP-346086 (24 h) inhibits apolipoprotein B (apoB) and triglyceride secretion (IC50=2.6 nM) from Hep-G2 cells without affecting apoA-I secretion or lipid synthesis[1]. |
In Vivo | CP-346086 (1-100 mg/kg; oral gavage once daily for 2 weeks) reduces plasma total, VLDL, and LDL cholesterol and triglycerides in mice[1]. CP-346086 (25 mg/kg; a single p.o.) results in an almost complete inhibition of Tyloxapol-induced triglyceride accumulation in fasted rats[1]. CP-346086 (0.1-10 mg/kg; a single p.o.) reduces acute plasma triglyceride in mice[1]. Animal Model: B6CBAF1J mice[1] Dosage: 1, 2, 10, 20, 100 mg/kg Administration: Oral gavage once daily for 2 weeks Result: Lowered total, VLDL, and LDL cholesterol and triglycerides dose dependently with 23%, 33%, 75%, and 62% reductions at 10 mg/kg/day. |
References |
Molecular Formula | C26H26F3N5O3 |
---|---|
Molecular Weight | 513.51 |